

# Hidekazu Sugiura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8593869/publications.pdf>

Version: 2024-02-01

32  
papers

1,006  
citations

567281  
15  
h-index

477307  
29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1254  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative Stress Decreases Klotho Expression in a Mouse Kidney Cell Line. Nephron Experimental Nephrology, 2005, 101, e67-e74.	2.2	165
2	Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrology Dialysis Transplantation, 2005, 20, 2636-2645.	0.7	151
3	Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. American Journal of Physiology - Renal Physiology, 2012, 302, F1252-F1264.	2.7	146
4	Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrology Dialysis Transplantation, 2010, 25, 60-68.	0.7	91
5	ATF3 Protects against Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 217-224.	6.1	67
6	Effect of Single-Dose Rituximab on Primary Glomerular Diseases. Nephron Clinical Practice, 2011, 117, c98-c105.	2.3	54
7	Circulating levels of soluble $\beta$ -Klotho in patients with chronic kidney disease. Clinical and Experimental Nephrology, 2011, 15, 795-796.	1.6	50
8	Risk Factors for Progression in Patients with Early-stage Chronic Kidney Disease in the Japanese Population. Internal Medicine, 2008, 47, 1859-1864.	0.7	39
9	The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clinical and Experimental Nephrology, 2007, 11, 214-217.	1.6	29
10	Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis. Physiological Reports, 2013, 1, e00172.	1.7	28
11	Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome. Internal Medicine, 2009, 48, 1901-1904.	0.7	27
12	Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease. Clinical and Experimental Nephrology, 2010, 14, 573-577.	1.6	23
13	Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model. PLoS ONE, 2018, 13, e0191706.	2.5	21
14	Recombinant Human Erythropoietin Mitigates Reductions in Renal Klotho Expression. American Journal of Nephrology, 2010, 32, 137-144.	3.1	20
15	Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. International Urology and Nephrology, 2012, 44, 841-845.	1.4	19
16	Ruptured Arterial Aneurysm of the Kidney in a Patient with Microscopic Polyangiitis. Internal Medicine, 2008, 47, 521-526.	0.7	15
17	Association between clinical characteristics and AL amyloid deposition in the kidney. Heart and Vessels, 2010, 25, 543-548.	1.2	10
18	Frequency of Renal Disease in Japan: An Analysis of 2,404 Renal Biopsies at a Single Center. Nephron Clinical Practice, 2010, 115, c227-c236.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Risedronate Therapy for the Prevention of Steroid-induced Osteoporosis in Patients with Minimal-change Nephrotic Syndrome. Internal Medicine, 2010, 49, 2065-2070.	0.7	7
20	CD2AP Expression in a Renal Ischemia/Reperfusion Injury Model and Analysis of Its Related Genes Using Overexpression and RNA Interference Technique. American Journal of Nephrology, 2005, 25, 373-381.	3.1	6
21	Three cases of late-onset oligomeganephronia. CKJ: Clinical Kidney Journal, 2011, 4, 14-16.	2.9	6
22	Hyperammonemia with intermittent loss of consciousness caused by chronic portal-systemic shunt encephalopathy (CPSE) in hemodialysis patient-A case report. Nihon Toseki Igakkai Zasshi, 2007, 40, 445-450.	0.1	6
23	Pharmacokinetics of Orally Administered Tacrolimus in Lupus Nephritis Patients. Yakugaku Zasshi, 2010, 130, 113-118.	0.2	5
24	Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients. Clinical and Experimental Nephrology, 2011, 15, 893-899.	1.6	5
25	Combined IgG4 <sup>+</sup> and IgG1 <sup>+</sup> deposition in the glomerular and tubular basement membrane accompanied by autoimmune neutropenia (AIN) and immune thrombocytopenia (ITP). CEN Case Reports, 2015, 4, 206-211.	0.9	2
26	Three cases of abdominal angina in patients with chronic renal failure: successful treatment with prostaglandin E1. Nihon Toseki Igakkai Zasshi, 2004, 37, 329-334.	0.1	2
27	Anti-Glomerular Basement Membrane Antibody Disease with Granulomatous Lesions on Renal Biopsy. Internal Medicine, 2007, 46, 295-301.	0.7	1
28	Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome. Case Reports in Nephrology, 2019, 2019, 1-4.	0.4	1
29	6714ŽKlothoãè...Žæ€šè²šè¡€ã«ã•ã•ã,Šã€ã;ã,«ã•14Ÿ. Nihon Toseki Igakkai Zasshi, 2009, 42, 831-833.	0.1	1
30	A case of pulmonary dialysis-related amyloidosis with reticular opacity of the lung in a patient undergoing long-term dialysis. CKJ: Clinical Kidney Journal, 2011, 4, 39-41.	2.9	0
31	A case report: The effect of Darubepoietin in a 64-year-old man on hemodialysis with pure red cell aplasia and adrenal dysfunction. Nihon Toseki Igakkai Zasshi, 2009, 42, 339-344.	0.1	0
32	Pulmonary embolism developing during thalidomide therapy for multiple myeloma in a hemodialysis patient. Nihon Toseki Igakkai Zasshi, 2011, 44, 951-956.	0.1	0